The European Patent Office (EPO) has granted WEHI a patent for CISH knockout (KO) in Natural Killer (NK) cells which is exclusively licensed to ONK Therapeutics for cell immunotherapy purposes, giving ...
NEW YORK and CAMBRIDGE, England, May 1, 2025 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancers, presented data from a ...
GALWAY, Ireland & SAN DIEGO, USA--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into an exclusive global patent ...
Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.
Skilled Staff – Agri-professionals who should be Graduate/ Post Graduate in Agriculture/Horticulture with five years of experience in this sector. Project Assistant ...
Background Chromogenic in situ hybridization (CISH) is fast becoming a well established technique for easy and sensitive determination of HER2 gene status in breast cancer. However, for the ...
a) Significant different from CISH ratio in a two tailed, paired t-test (N = 348, P < 0.001) b) Significant different from CISH ratio in a two tailed, paired t-test (N = 350, P = 0.001) c) Not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results